Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma

Journal of Surgical Oncology

Volumn 105, Issue 3, 2012, Pages 235-243

  Wang, Yin He ^a   Han, Xiao Dong ^b   Qiu, Yong ^a   Xiong, Jin ^a   Yu, Yang ^a   Wang, Bin ^a   Zhu, Ze Zhang ^a   Qian, Bang Ping ^a   Chen, Yi Xin ^a   Wang, Shou Feng ^a   Shi, Hong Fei ^a   Sun, Xu ^a  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

insulin like growth factor 1 receptor; metastasis; osteosarcoma; overall survival; prognosis

Indexed keywords

PROTEIN KINASE B; SOMATOMEDIN C;

ADULT; ARTICLE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HAZARD RATIO; HUMAN; HUMAN TISSUE; LENTIVIRINAE; MALE; METASTASIS; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SURVIVAL; WESTERN BLOTTING;

ADULT; ANIMALS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LENTIVIRUS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; OSTEOSARCOMA; PROGNOSIS; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84860389568     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22077     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96. (Pubitemid 351521864)
2. Ta HT, Dass CR, Choong PF, et al.: Osteosarcoma treatment: State of the art. Cancer Metastasis Rev 2009; 28: 247-263.
3. Bispo JÃnior RZ, Camargo OP,: Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy. Clinics (Sao Paulo) 2009; 64: 1177-1186.
4. Adams TE, Epa VC, Garrett TP, et al.: Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000; 57: 1050-1093. (Pubitemid 30598754)
5. Werner H, Bruchim I,: The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 2009; 115: 58-71.
6. Bohula EA, Playford MP, Macaulay VM,: Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs 2003; 14: 669-682. (Pubitemid 37357691)
7. Macaulay VM,: The IGF receptor as anticancer treatment target. Novartis Found Symp 2004; 262: 235-243.
8. Wang YH, Wang ZX, Qiu Y, et al.: Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells. Mol Cell Biochem 2009; 327: 257-266.
9. Wang YH, Xiong J, Wang SF, et al.: Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo. Mol Cell Biochem 2010; 341: 225-233.
10. Siddle K,: The insulin receptor and type I IGF receptor: Comparison of structure and function. Prog Growth Factor Res 1992; 4: 301-320.
11. Werner H, Adamo M, Roberts CT Jr., et al.: Molecular and cellular aspects of insulin-like growth factor action. Vitam Horm 1994; 48: 1-58.
12. Koda M, Reszec J, Sulkowska M, et al.: Expression of the insulin-like growth factor-I receptor and proapoptotic Bax and Bak proteins in human colorectal cancer. Ann N Y Acad Sci 2004; 1030: 377-383. (Pubitemid 40378936)
13. Kim WY, Jin Q, Oh SH, et al.: Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res 2009; 69: 7439-7448.
14. Kuramoto H, Hongo A, Liu YX, et al.: Immunohistochemical evaluation of insulin-like growth factor I receptor status in cervical cancer specimens. Acta Med Okayama 2008; 62: 251-259.
15. Shimizu C, Hasegawa T, Tani YT, et al.: Expression of insulin-like growth factor 1 receptor in primary breast cancer: Immunohistochemical analysis. Hum Pathol 2004; 35: 1537-1542. (Pubitemid 40017995)
16. Kaleko M, Rutter WJ, Miller AD,: Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 1990; 10: 464-473.
17. Liu S, Jin F, Dai W, et al.: Antisense treatment of IGF-IR enhances chemosensitivity in squamous cell carcinomas of the head and neck. Eur J Cancer 2010; 46: 1744-1751.
18. Kolb EA, Gorlick R,: Development of IGF-IR inhibitors in pediatric sarcomas. Curr Oncol Rep 2009; 11: 307-313.
19. Yeh J, Litz J, Hauck P, et al.: Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Lung Cancer 2008; 60: 166-174. (Pubitemid 351609143)
20. Kim JH, Cho YH, Park YL, et al.: Prognostic significance of insulin growth factor-I receptor and insulin growth factor binding protein-3 expression in primary breast cancer. Oncol Rep 2010; 23: 989-995.
21. Kalinina T, Bockhorn M, Kaifi JT, et al.: Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus. Int J Cancer 2010; 127: 1931-1940.
22. Sichani MM, Yazdi FS, Moghaddam NA, et al.: Prognostic value of insulin-like growth factor-I receptor expression in renal cell carcinoma. Saudi J Kidney Dis Transpl 2010; 21: 69-74.
23. Ge J, Chen Z, Wu S, et al.: Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion 2009; 80: 148-158.
24. Clark JC, Dass CR, Choong PF,: A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008; 134: 281-297. (Pubitemid 351170066)
25. Davis AM, Bell RS, Goodwin PJ,: Prognostic factors in osteosarcoma: A critical review. J Clin Oncol 1994; 12: 423-431. (Pubitemid 24056419)
26. Zhang D, Samani AA, Brodt P,: The role of the IGF-I receptor in the regulation of matrix metalloproteinases, tumor invasion and metastasis. Horm Metab Res 2003; 35: 802-808. (Pubitemid 38058186)
27. Brodt P, Samani A, Navab R,: Inhibition of the type I insulin-like growth factor receptor expression and signaling: Novel strategies for antimetastatic therapy. Biochem Pharmacol 2000; 60: 1101-1107.
28. Klein G, Vellenga E, Fraaije MW, et al.: The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol 2004; 50: 87-100. (Pubitemid 38638736)
29. John A, Tuszynski G,: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001; 7: 14-23. (Pubitemid 32591662)
30. Chapuis N, Tamburini J, Cornillet-Lefebvre P, et al.: Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: Therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 2010; 95: 415-423.
31. Qian J, Dong A, Kong M, et al.: Suppression of type 1 Insulin-like growth factor receptor expression by small interfering RNA inhibits A549 human lung cancer cell invasion in vitro and metastasis in xenograft nude mice. Acta Biochim Biophys Sin (Shanghai) 2007; 39: 137-147.